Photo Credit: Christoph Burgstedt
The Following is a summary of “Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet Therapy in PCI Patients: A Systematic Review and Meta-Aalysis,” Published in the January 2025 Issue of Cardiology by Alagna et al.
Dual Antiplatelet Therapy (DAPT) with aspirin and a p2y12 Inhibitor exists as The Standard Post-Post-CORONARY INTERVENTION (PCI) with Drug-LEVERS (DES), Buttimal Duration Remains Ambiguous Due to the competition risk of ischemic events and Bleeding.
Researchers Drived the Retrospective Study to Evaluate The Effficial and Safety Monotherapy After Short-Duation Dapt (1-3 months) Compred to Extended DAPT, Focusing on Major Bleeding and Cardiovascular Outcomes.
They Analyzed Randomized Controlled Trials (RCTS) Comparing Ticagrelor Monotherapy After Short-Duation Dapt with Extended Dapt, Sourced from Pubmed, and the Cochrane Library and Focused On Major Bleeding, Major Adverse Cardiovascular Events (Macce) Ction, Stroke , stent thrubosis, and mortality. Risk Ratios (RR) with 95% CI WERE CALCULATED USING A RANDOM-EFFETS MODEL.
The Results Showed 5 RCTS with 32,393 Patients Demoned that Ticagrelor Monotherapy Significantly Reduced Macce (RR: 0.88; 95% CI: 0.77-0.99; P = 0.04) and Major Bleeding (RR: 0.53; 95% CI: 0.37-0.77; P = 0.0008) Compred to extended dapt. TICAGRELOR ALSO REDUCED ALL-CAUSE MORTALITY (RR: 0.82; 95% CI: 0.67-0.99; P = 0.04) and death cardiovascular (RR: 0.68; 95% CI: 0.49-0.94; P = 0.02). The Rates of Myocardial Infarction, Stent Thrombosis, and Stroke Were similar Beteeen the Groups. NET ADVERSE CLINICAL EVENTS (NACE) WERE 27% LOWER WITH TICAGRELOR MONOTHERAPY (RR: 0.73; 95% CI: 0.63-0.85; P <0.0001).
Investigators Concluded the Ticagrelor Monotherapy After Short-Duation Dapt Reduced Major Bleeding Complications While Cardiovascular Protection, Offering The Promising Strategy for Patients with PCI, specially those at High Bleeding Risk.
Source: ajconline.org/article/s0002-9149(25)00041-4/fulltext
